Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion...
Neurophth Biotechnology
Neurophth Biotechnology’s NFS-05 Gene Therapy Gets Australian Clinical Trial Approval for ADOA
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that it has received clinical trial...
Neurophth Biotechnology Secures RMB700 Million in Series C+ Financing for Gene Therapy Development
China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in...
Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...
Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...
Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...
Neurophth Partners with Apellis for Gene Therapy Development in AMD
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with US firm...
Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval...
Cyagen Biosciences Partners with Neurophth for Ophthalmology AAV Capsid Development
Cyagen Biosciences, a provider of custom-engineered mouse and rat models with operations in the US...
Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been...
Neurophth and Abogen Partner on mRNA Therapy for Retinal Diseases
China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...
Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy
China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth...